Evidence map›Paper›PMID 32692871›Full record

ArticleThe Prostate2020

Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.

Jagpreet S Nanda, Wisam N Awadallah, Sarah E Kohrt, Petra Popovics, Justin M M Cates, Janni Mirosevich, Peter E Clark, Giovanna A Giannico, Magdalena M Grabowska

Open access · greenAbstract read
In one paragraph

Article in The Prostate, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jagpreet S NandaDepartment of Urology, Case Western Reserve University, Cleveland, Ohio.ORCID 0000-0002-8096-7654
Wisam N AwadallahDepartment of Urology, Case Western Reserve University, Cleveland, Ohio.ORCID 0000-0002-8209-1940
Sarah E KohrtCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.ORCID 0000-0002-9754-8894
Petra PopovicsDepartment of Urology, Case Western Reserve University, Cleveland, Ohio.ORCID 0000-0002-9179-0575
Justin M M CatesDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-7336-5196
Janni MirosevichDepartment of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Peter E ClarkDepartment of Urology, Levine Cancer Center/Atrium Health, Charlotte, North Carolina.ORCID 0000-0002-8006-7015
Giovanna A GiannicoDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-0326-3207
Magdalena M GrabowskaDepartment of Urology, Case Western Reserve University, Cleveland, Ohio.ORCID 0000-0003-1550-4925
Case Western Reserve University · USVanderbilt University Medical Center · USLevine Cancer Institute · US

Funding

PREDOCTORAL TRAINING PROGRAM IN MOLECULAR THERAPEUTICST32GM008803 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI MIEYAL, JOHN J, NIEMAN, MARVIN THOMAS · 2001 to 2023
$4.2M
Nuclear Factor I/B Action in Castrate Resistant Prostate CancerR00CA197315 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GRABOWSKA, MAGDALENA MALGORZATA · 2017 to 2019
$668k
Nuclear Factor I/B Action in Castrate Resistant Prostate CancerK99CA197315 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GRABOWSKA, MAGDALENA MALGORZATA · 2015 to 2016
$185k
NCI NIH HHS K99 CA197315NCI NIH HHS R00 CA197315NIGMS NIH HHS T32 GM008803NIH HHS K99CA197315NIH HHS R00CA197315
6 · The paper itself

Abstract

backgroundMost prostate cancers express androgen receptor (AR), and our previous studies have focused on identifying transcription factors that modify AR function. We have shown that nuclear factor I/B (NFIB) regulates AR activity in androgen-dependent prostate cancer cells in vitro. However, the status of NFIB in prostate cancer was unknown.

methodsWe immunostained a tissue microarray including normal, hyperplastic, prostatic intraepithelial neoplasia, primary prostatic adenocarcinoma, and castration-resistant prostate cancer tissue samples for NFIB, AR, and synaptophysin, a marker of neuroendocrine differentiation. We interrogated publically available data sets in cBioPortal to correlate NFIB expression and AR and neuroendocrine prostate cancer (NEPCa) activity scores. We analyzed prostate cancer cell lines for NFIB expression via Western blot analysis and used nuclear and cytoplasmic fractionation to assess where NFIB is localized. We performed co-immunoprecipitation studies to determine if NFIB and AR interact.

resultsNFIB increased in the nucleus and cytoplasm of prostate cancer samples versus matched normal controls, independent of Gleason score. Similarly, cytoplasmic AR and synaptophysin increased in primary prostate cancer. We observed strong NFIB staining in primary small cell prostate cancer. The ratio of cytoplasmic-to-nuclear NFIB staining was predictive of earlier biochemical recurrence in prostate cancer, once adjusted for tumor margin status. Cytoplasmic AR was an independent predictor of biochemical recurrence. There was no statistically significant difference between NFIB and synaptophysin expression in primary and castration-resistant prostate cancer, but cytoplasmic AR expression was increased in castration-resistant samples. In primary prostate cancer, nuclear NFIB expression correlated with cytoplasmic NFIB and nuclear AR, while cytoplasmic NFIB correlated with synaptophysin, and nuclear and cytoplasmic AR. In castration-resistant prostate cancer samples, NFIB expression correlated positively with an AR activity score, and negatively with the NEPCa score. In prostate cancer cell lines, NFIB exists in several isoforms. We observed NFIB predominantly in the nuclear fraction of prostate cancer cells with increased cytoplasmic expression seen in castration-resistant cell lines. We observed an interaction between AR and NFIB through co-immunoprecipitation experiments.

conclusionWe have described the expression pattern of NFIB in primary and castration-resistant prostate cancer and its positive correlation with AR. We have also demonstrated AR interacts with NFIB.

Indexed as

Cell Line, TumorGene ExpressionHumansImmunohistochemistryMaleNFI Transcription FactorsProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantReceptors, AndrogenTissue Array AnalysisTranscriptomeAR protein, humanNFIB protein, humanNFI Transcription FactorsReceptors, Androgenandrogen receptorNFIBprostate cancer

Identifiers

PMID32692871
PMCPMC7434711
OpenAlexW3045407788

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.